Table 3.
Genotypes | All patients with ACS n (%) |
STEMI n (%) |
NSTEMI n (%) |
Control group n (%) |
---|---|---|---|---|
ACE I/D | ||||
II | 117 (22.5) | 89 (22.8) | 28 (21.7) | 165 (25.6) |
ID | 317 (61.1)* | 236 (60.5)* | 81 (62.8)* | 339 (52.6) |
DD | 85 (16.4)* | 65 (16.7)* | 20 (15.5)* | 141 (21.9) |
ID + II | 434 (83.6)* | 325 (83.3)* | 109 (84.5) | 504 (78.1) |
DD | 85 (16.4) | 65 (16.7) | 20 (15.5) | 141 (21.9) |
MMP-2 –735 C/T | ||||
CC | 412 (79.4) | 306 (78.7) | 106 (81.5) | 504 (78.1) |
CT | 100 (19.3) | 78 (20.1) | 22 (16.9) | 126 (19.5) |
TT | 7 (1.3) | 5 (1.3) | 2 (1.5) | 15 (2.3) |
TT + CT | 107 (20.6) | 83 (21.3) | 24 (18.5) | 141 (21.9) |
CC | 412 (79.4) | 307 (78.7) | 106 (81.5) | 504 (78.1) |
MMP-2 –1306 C/T | ||||
CC | 312 (59.9) | 235 (60.1) | 77 (59.2) | 369 (57.2) |
CT | 175 (33.6) | 130 (33.2) | 45 (34.6) | 237 (36.7) |
TT | 34 (6.5) | 26 (6.6) | 8 (6.2) | 39 (6.0) |
CC + CT | 487 (93.5) | 366 (93.4) | 122 (93.8) | 606 (94.0) |
TT | 34 (6.5) | 26 (6.6) | 8 (6.2) | 39 (6.0) |
MMP-3 5A/6A | ||||
5A5A | 145 (27.7)* | 114(29.0)*# | 31 (23.8)# | 151 (23.4) |
5A6A | 269 (51.4) | 206 (52.4) | 63 (48.5) | 325 (50.4) |
6A6A | 109 (20.8)* | 73 (18.6)*# | 36 (27.7)# | 169 (26.2) |
5A5A + 5A6A | 414 (79.2)* | 321 (81.5)*# | 94 (72.3)# | 475 (73.6) |
6A6A | 109 (20.8) | 73 (18.5) | 36 (27.7) | 170 (26.4) |
MMP-9 C/T | ||||
TT | 22 (4.2) | 17 (4.4) | 5 (3.8) | 29 (4.5) |
CT | 156 (30.1) | 113 (29.1) | 43 (33.1) | 185 (28.7) |
CC | 340 (65.6) | 258 (66.5) | 82 (63.1) | 431 (66.8) |
TT + CT | 178 (34.4) | 131 (33.7) | 48 (36.9) | 214 (33.2) |
CC | 340 (65.6) | 258 (66.3) | 82 (63.1) | 431 (66.8) |
P<0.05 if comparing between ACS patients (STEMI and/or NSTEMI) and control group.
P<0.005 if comparing between STEMI and NSTEMI patients. ACE: angiotensin converting enzyme; ACS: acute coronary syndrome; STEMI: ST elevation myocardial infarction; NSTEMI: non-ST elevation myocardial infarction; I: insertion; D: deletion; MMP: matrix metalloproteinase; T: thymine; C: cytosine; A: adenine.